[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341306-105":59,"doc-detail-341306-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genomic-and-transcriptomic-landscape-of-ret-wildtype-medullary-thyroid-cancer-and-potential-use-of-mitogen-activated-protein-kinase-targeted-therapy","Genomic and Transcriptomic Landscape of RET WildType Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy","","Medullary thyroid cancer (MTC) is frequently driven by RET mutations, yet wild-type RET (wtRET) MTC still requires effective therapeutic options. A retrospective analysis assessed genomic alterations, transcriptomic signatures, and programmed cell death ligand 1 (PD-L1) expression across MTC samples submitted for DNA/RNA sequencing and immunohistochemistry. In a 160-patient cohort, wtRET tumors showed distinct MAPK pathway mutations, higher tumor mutational burden, and increased immune checkpoint gene expression, supporting differentiated biology and potential MAPK-targeted strategies. Findings also inform combinational immuno-oncology approaches for selected wtRET patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomic-and-transcriptomic-landscape-of-ret-wildtype-medullary-thyroid-cancer-and-potential-use-of-mitogen-activated-protein-kinase-targeted-therapy/341306/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomic-and-transcriptomic-landscape-of-ret-wildtype-medullary-thyroid-cancer-and-potential-use-of-mitogen-activated-protein-kinase-targeted-therapy/341306.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does RET mutation play in medullary thyroid cancer, according to the study?","Question",{"text":112,"@type":113},"About 45% to 70% of sporadic MTCs are driven by RET mutations. The study notes that treatments exist for RET-mutated MTC, but options are needed for wild-type RET MTC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers characterize genomic and transcriptomic differences between wtRET and mutRET tumors?",{"text":117,"@type":113},"They performed DNA/RNA sequencing and assessed PD-L1 by immunohistochemistry. Tumor microenvironment immune fractions were estimated using RNA deconvolution (quanTIseq), and transcriptomic inflammation and MAPK pathway activation scores were calculated.",{"name":119,"@type":110,"acceptedAnswer":120},"What key biological distinctions were observed in wtRET MTC?",{"text":121,"@type":113},"wtRET tumors frequently carried MAPK pathway mutations, had higher tumor mutational burden, and showed higher expression of immune checkpoint genes compared with mutRET tumors. While PD-L1 expression frequency was similar between groups, molecular and immune-related features distinguished wtRET from mutRET MTC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341306,1790167569,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Genomic and Transcriptomic Landscape of RET WildType Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy  \nSourat Darabi, PhD, MS, Tolulope Adeyelu, PhD, Andrew Elliott, PhD, Ammar Sukari, MD, Kurt Hodges, MD, Farah Abdulla, MD, Carlos E Zuazo, MSc, Trisha Wise-Draper, MD, PhD, Thomas Wang, MD, PhD, FACS, Michael J Demeure, MD, MBA, FACS  \n\n| BACKGROUND:\u003Cbr>STUDY DESIGN:\u003Cbr>RESULTS:\u003Cbr>CONCLUSIONS: | About 75% of medullary thyroid cancers (MTCs) are sporadic with 45% to 70% being driven by a RET mutation. Selpercatinib is an approved treatment for RET-mutated (mutRET) MTC; however, treatments are needed for wild-type RET MTC (wtRET) . Genomic alterations and transcriptomic signatures ofwtRETMTC may reveal new therapeutic insights. We did a retrospective analysis of MTC samples submitted for DNA/RNA sequencing and programmed cell death ligand 1 expression using immunohistochemistry at a Clinical Laboratory Improvement Amendments/College of American Pathologists-certified laboratory. Tumor microenvironment immune cell fractions were estimated using RNA deconvolution (quanTIseq). Transcriptomic signatures of inflammation and MAP kinase pathway activation scores were calculated. Mann-Whitney U, chi-square, and Fisher’s exact tests were applied (p values adjusted for multiple comparisons) .\u003Cbr>The 160-patient cohort included 108 mutRET and 52 wtRET MTC samples. wtRET tumors frequently harbored mitogen-activated protein kinase (MAPK) pathway mutations, including HRAS (42.31%), KRAS (15.7%), NF1 (6.7%), and BRAF(2%), whereas only 1 MAPK pathway mutation (NF1) was identified among mutRET MTC. Recurrent mutations seen in wtRET MTC included MGA, VHL, APC, STK11, and NFE2L2. Increased transcriptional activation of the MAPK pathway was observed in patients with wtRET harboring mutations in MAPK genes. Although the frequency of programmed cell death ligand 1 expression was similar in wtRETand mutRET(10.2% vs 7%, p = 0.531), wtRET tumors were more often tumor mutational burden high (7.7% vs 0%, p = 0.011), and wtRET MTC exhibited higher expression of immune checkpoint genes. We identified molecular alterations and immune-related features that distinguish wtRET from mutRET MTC. Although RET mutation drives MTC in the absence of other alterations, we showed that wtRET MTC frequently harbors MAPK pathway mutations. These findings may indicate a potential basis for MAPK-targeted therapy, possibly in combination with immunooncology agents for selected patients with wtRET MTC. (JAm Coll Surg 2024;239:50–60. © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American College of Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 [CCBY-NC-ND], where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in anyway or used commercially without permission from the journal.) |\n| --- | --- |\n\nDisclosure Information: Dr Demeure receives consulting fees from Lilly, Orphagen, Theralink, Bayer, TD2 OnCusp, Pfizer, Aadi Biosciences, Corcept, and Crinetics. Drs Adeyelu, Elliott, Oberley, and Abdulla are employees of Caris Life Sciences. Dr Darabi receives consulting fees from BostonGene. Other authors have nothing to disclose.  \nDisclosures outside the scope of this work: Dr Wise-Draper receives consulting fees from Caris Life Sciences, Merck, EMD Serono, and Adlai, and receives clinical trial funding from Merck, BMS, Astrazeneca, and Janssen, Tesaro/GSK.  \nPresented at the Western Surgical Association 131st Scientific Session, Dana Point, CA, November 2023.  \nReceived January 2, 2024; Revised March 25, 2024; Accepted April 3, 2024. From the Cancer Institute, Hoag Memorial Hospital, Newport Beach, CA (Darabi, Zuazo, Wang, Demeure); Clinical and Translational Research, Caris Life Science, Phoenix, AZ (Adeyelu, Elliott, Hodges, Abdulla); Departm","cbCailIL5EIGb1K0","https://ap.wps.com/l/cbCailIL5EIGb1K0","pdf",4538382,11,"English","# Background\n## Study design\n## Results\n## Conclusions\n# Methods and cohort\n## Genomic alterations and transcriptomic signatures\n## PD-L1 and immune microenvironment estimation\n# Clinical and molecular findings\n## MAPK pathway mutations in wtRET vs mutRET\n## Tumor mutational burden and immune checkpoint gene expression\n# Implications for therapy","[{\"question\":\"What role does RET mutation play in medullary thyroid cancer, according to the study?\",\"answer\":\"About 45% to 70% of sporadic MTCs are driven by RET mutations. The study notes that treatments exist for RET-mutated MTC, but options are needed for wild-type RET MTC.\"},{\"question\":\"How did the researchers characterize genomic and transcriptomic differences between wtRET and mutRET tumors?\",\"answer\":\"They performed DNA/RNA sequencing and assessed PD-L1 by immunohistochemistry. Tumor microenvironment immune fractions were estimated using RNA deconvolution (quanTIseq), and transcriptomic inflammation and MAPK pathway activation scores were calculated.\"},{\"question\":\"What key biological distinctions were observed in wtRET MTC?\",\"answer\":\"wtRET tumors frequently carried MAPK pathway mutations, had higher tumor mutational burden, and showed higher expression of immune checkpoint genes compared with mutRET tumors. While PD-L1 expression frequency was similar between groups, molecular and immune-related features distinguished wtRET from mutRET MTC.\"}]","Genomic and Transcriptomic Landscape of RET WildType Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy | PDF",1790041472,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0065090cc5c2ab4372bcddfcdcd6c709.webp",983,1320,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1656d63997ddfa53163bb9a087ee6944.webp",982,1319,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be0e97a756bc16b213a994f48eadc271.webp",981,1318,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0f273d9bc8092b91f66f1502efa5c0e.webp",980,1316]